Acute Radiation Syndrome

U.S. FDA clears Humanetics' IND filing to commence clinical studies on new radiation countermeasure

Published in Medical Device Business Week, February 7th, 2007

Humanetics Corporation announced that the U.S. Food and Drug Administration (FDA) has cleared the company's request to begin Phase I human trials under an Investigational New Drug (IND) application for BIO 300, a radiation countermeasure.

Humanetics is seeking approval to market BIO 300 as a new oral drug for the prevention and prophylactic treatment of acute radiation syndrome (ARS).

ARS is a potentially lethal condition that may be caused by whole-body exposure to radiation resulting from a nuclear or radiological terrorist attack or from an accident at a nuclear facility. Exposure to radiation causes injury to bone marrow, resulting in decreased...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Device Business Week

Source: Medical Device Business Week (2007-02-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry